Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthcare Services (HCSG) Cash & Equivalents (2016 - 2026)

Healthcare Services has reported Cash & Equivalents over the past 18 years, most recently at $136.2 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 111.72% to $136.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $136.2 million through Mar 2026, up 111.72% year-over-year, with the annual reading at $125.2 million for FY2025, 120.5% up from the prior year.
  • Cash & Equivalents was $136.2 million for Q1 2026 at Healthcare Services, up from $125.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $136.2 million in Q1 2026 and troughed at $16.2 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $31.7 million (2022), against an average of $53.7 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 75.33% in 2022 and later soared 359.76% in 2025.
  • Tracing HCSG's Cash & Equivalents over 5 years: stood at $26.3 million in 2022, then skyrocketed by 106.74% to $54.3 million in 2023, then rose by 4.5% to $56.8 million in 2024, then skyrocketed by 120.5% to $125.2 million in 2025, then rose by 8.77% to $136.2 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $136.2 million, $125.2 million, and $124.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.